Editorial - International Journal of Clinical Rheumatology (2024) Volume 19, Issue 3
Unlocking the Secrets of Osteopenia: Understanding, Prevention, and Management
Adaba Baoro*
Department of Medicine, Bayero University, Kano, Nigeria
- *Corresponding Author:
- Adaba Baoro
Department of Medicine, Bayero University, Kano, Nigeria
E-mail: adaba45@yahoo.com
Abstract
Osteopenia, a term derived from the Greek words "osteo" meaning bone and "penia" meaning poverty, refers to a condition characterized by lower than normal bone mineral density (BMD). While not as severe as osteoporosis, osteopenia is considered a precursor to this more advanced bone-weakening condition. In this article, we will explore the intricacies of osteopenia, including its causes, risk factors, diagnosis, prevention strategies, and management options.
Keywords
Osteopenia • Joint pain • Rheumatology
Introduction
Bone is a dynamic tissue that undergoes a constant process of remodeling, with old bone being replaced by new bone. Osteopenia occurs when the rate of bone resorption (breakdown) exceeds the rate of bone formation, resulting in a gradual loss of bone density over time. While osteopenia does not typically cause symptoms, it can increase the risk of fractures and may progress to osteoporosis if left untreated [1-3].
Methodology
Causes and risk factors
Several factors can contribute to the development of osteopenia, including:
Age: Bone density naturally decreases with age, making older adults more susceptible to osteopenia and osteoporosis.
Gender: Women are at higher risk of osteopenia and osteoporosis, especially after menopause when estrogen levels decline.
Hormonal imbalances: Conditions that disrupt hormone levels, such as hyperthyroidism or hypogonadism, can affect bone health and increase the risk of osteopenia.
Nutritional deficiencies: Inadequate intake of calcium, vitamin D, and other nutrients essential for bone health can impair bone formation and increase the risk of osteopenia.
Sedentary lifestyle: Lack of weight-bearing exercise and physical activity can lead to bone loss and weaken bone density over time.
Smoking and alcohol consumption: Tobacco use and excessive alcohol intake can interfere with calcium absorption and contribute to bone loss [4-6].
Medications: Certain medications, such as corticosteroids, anticonvulsants, and proton pump inhibitors, can weaken bones and increase the risk of osteopenia.
Diagnosis of osteopenia
Osteopenia is typically diagnosed using a bone density test, also known as dual-energy X-ray absorptiometry (DXA) scan. This non-invasive imaging technique measures bone mineral density at various sites, such as the hip and spine, and compares the results to those of healthy young adults to determine if bone density is within the normal range.
The World Health Organization (WHO) defines osteopenia as a T-score between -1.0 and -2.5 standard deviations below the peak bone mass of young adults. A T-score between -1.0 and -2.5 indicates low bone density or osteopenia, while a T-score of -2.5 or lower is indicative of osteoporosis.
Prevention strategies
Preventing osteopenia and reducing the risk of osteoporosis involves adopting healthy lifestyle habits and addressing modifiable risk factors. Key prevention strategies include:
Adequate nutrition: Consuming a balanced diet rich in calcium, vitamin D, protein, and other nutrients essential for bone health can help support bone formation and prevent bone loss [7-9].
Weight-bearing exercise: Engaging in weight-bearing activities such as walking, jogging, dancing, and resistance training can help strengthen bones and improve bone density.
Smoking cessation: Quitting smoking can help preserve bone health and reduce the risk of osteopenia and osteoporosis.
Limiting alcohol intake: Moderating alcohol consumption to no more than one drink per day for women and two drinks per day for men can help protect against bone loss.
Fall prevention: Taking steps to prevent falls, such as removing hazards from the home, installing grab bars and handrails, and practicing balance exercises, can reduce the risk of fractures in individuals with osteopenia.
Management options
If diagnosed with osteopenia, healthcare providers may recommend various management options to help slow the progression of bone loss and reduce the risk of fractures. These may include:
Calcium and vitamin D supplements: Supplementing with calcium and vitamin D may be recommended for individuals with low dietary intake or inadequate sun exposure to support bone health.
Medications: In some cases, healthcare providers may prescribe medications such as bisphosphonates, selective estrogen receptor modulators (SERMs), or monoclonal antibodies to help increase bone density and reduce the risk of fractures.
Regular monitoring: Individuals with osteopenia may undergo periodic bone density testing to monitor changes in bone density over time and assess the effectiveness of treatment.
Lifestyle modifications: Adopting lifestyle modifications such as regular exercise, smoking cessation, and alcohol moderation can help optimize bone health and reduce the risk of osteoporotic fractures [10].
Living well with osteopenia
While osteopenia may increase the risk of fractures and osteoporosis, it is not inevitable, and there are steps individuals can take to maintain bone health and reduce their risk of complications. By adopting a proactive approach to bone health through healthy lifestyle habits, regular exercise, adequate nutrition, and appropriate medical management, individuals with osteopenia can continue to lead active, fulfilling lives while minimizing the impact of this condition on their overall well-being.
Conclusion
In conclusion, osteopenia is a common condition characterized by lower than normal bone density, which increases the risk of fractures and may progress to osteoporosis if left untreated. By understanding the causes, risk factors, diagnosis, prevention strategies, and management options for osteopenia, individuals can take proactive steps to preserve bone health and reduce their risk of complications. Remember to consult with your healthcare provider for personalized guidance and recommendations tailored to your individual needs and risk factors.
References
- Arima H, Koirala S, Nema K et al. High prevalence of rheumatoid arthritis and its risk factors among Tibetan highlanders living in tsarang, mustang district of Nepal. J Physiol Anthropol. 41-12 (2022).
- Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 81,768-79 (2022).
- Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 76,17-28 (2017).
- Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open.6-e001032 (2020).
- Goodson NJ, Symmons DM, Scott DI et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum.52,2293-9(2005).
- Solomon A, Stanwix AE, Castaneda S et al. Points to consider in cardiovascular disease risk management among patients living in South Africa, an unequal middle-income country. BMC Rheumatol.4-42 (2020).
- Sofogianni A, Stalikas N, Antza C et al. Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine. J Pers Med. 20,12-1180 (2022).
- Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 4-481 (2016).
- Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 112,2078-80 (2005).
- Grundy S. Gamma-glutamyl transferase another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol .27,4-7(2007).
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
